Skip to main content
. Author manuscript; available in PMC: 2014 Nov 22.
Published in final edited form as: J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):e27–e33. doi: 10.1097/QAI.0000000000000252

Table 3. Risk factors for attrition and mortality of patients starting ART in Karonga District, 2005-2012*.

Attrition Mortality

Risk factor Unadjusted HR (95% CI) Adjusted HR (95% CI) P-value Unadjusted HR (95% CI) Adjusted HR (95% CI) P-value
Age <0.001 NS
 15-34 years 1.24 (1.12-1.37) 1.32 (1.19-1.46) 1.05 (0.91-1.21) 1.12 (0.97-1.29)
 ≥35 years 1 1 1 1
Gender <0.001 <0.001
 Male 1.39 (1.26-1.54) 1.49 (1.34-1.65) 1.54 (1.34-1.77) 1.61 (1.39-1.85)
 Female 1 1 1 1
Distance from clinic NS NS
 <5km 1 1 1 1
 5 - <10km 0.95 (0.83-1.08) 1.04 (0.91-1.20) 0.85 (0.70-1.04) 0.98 (0.80-1.19)
 10 - <25km 1.09 (0.96-1.24) 1.05 (0.92-1.19) 1.13 (0.94-1.35) 1.04 (0.86-1.24)
 ≥25km 1.64 (1.40-1.92) 1.04 (0.88-1.23) 1.95 (1.58-2.41) 0.98 (0.79-1.22)
Reason for starting ART <0.001 <0.001
 CD4 cell count criteria 1 1 1 1
 WHO stage 3 1.91 (1.56-2.35) 1.60 (1.30-1.97) 2.23 (1.60-3.12) 1.69 (1.20-2.37)
 WHO stage 4 3.98 (3.23-4.91) 2.51 (2.02-3.13) 6.65 (4.76-9.27) 3.27 (2.31-4.63)
Year of ART initiation <0.001 <0.001
 Per increasing calendar year 0.77 (0.75-0.79) 0.82 (0.79-0.84) 0.68 (0.66-0.71) 0.74 (0.71-0.77)
*

Complete data for 8,116 patients.

HR: Hazard Ratio; CI: Confidence Interval; NS: non-significant